The Clinical Importance of Fibroblast Growth Factor 23 on Breast Cancer Patients

Abstract

Objective: To investigate the relation between serum fibroblast growth factor (FGF) 23 levels and clinicopathologic features of breast cancer patients, by comparing healthy control group. Material and methods: This was a prospective, single-center study. Newly diagnosed stage 1- 4 breast cancer patients and healthy control in similar age, without any chronic disease and vitamin D deficiency were enrolled in the study. Fibroblast growth factor 23 levels were compared between groups. Results: Thirty eight women newly diagnosed stage 1 and 4 patients and 40 healty women were enrolled. The median age of patients and controls were 54 and 53.1 years. The number of patients were 7 (18.4%), 9 (23.7%), 13 (34.2%), 5 (13.2%), 1 (2.6%) and 3 (7.9%) in stage 1A, 2A, 2B, 3A, 3B and stage 4 groups respectively. The mean FGF 23 level was calculated as 167.4±177.2 pg/ml in patients group and 63.1±11.4 pg/ml in control group (p=0.0004). Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for breast cancer and is important in terms of suggesting the FGF pathway as a new treatment target in breast cancer patients.